This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Analysts' Actions: BAC, JCP, NTAP

Stocks in this article: BAC JCP NTAP SKS VPHM

Apple (AAPL) estimates, target were boosted at Sterne Agee. Shares are now seen reaching $750. Estimates were also increased, following channel checks, Sterne Agee. Buy rating.

Ball numbers were raised at Jefferies. Shares are now seen reaching $49. Estimates also raised on favorable rigids volume trends, Jefferies said. Buy rating.

Canadian Pacific Railway (CP) numbers were raised at Jefferies. Shares are now seen reaching $72. Estimates were also raised on first-quarter guidance, Jefferies said. Hold rating.

Forest Labs (FRX) numbers were cut at Credit Suisse. Shares are now seen reaching $44. Estimates were also reduced, given the company's new guidance, Credit Suisse said. Outperform rating.

First Solar (FSLR) numbers were cut at UBS. Shares are now seen reaching $23. Estimates were also lowered as module business is affecting system value, UBS said. Neutral rating.

Las Vegas Sands (LVS) numbers were increased at BMO Capital. Estimates were raised through 2013. Macau should continue to drive growth, BMO Capital said. Outperform rating and new $69 price target.

Priceline.com (PCLN) numbers were raised at Benchmark. Shares are now seen reaching $840. Estimates were also increased, given better industry trends and emerging market growth, Benchmark said. Buy rating.

Qlik Technologies (QLIK) price target was raised at Jefferies to $35. Survey suggests modest upside risk, Jefferies said. Buy rating.

VMware (VMW) price target was raised at Jefferies to $100. Improved current year growth expectations, Jefferies said. Hold rating.

ViroPharma Incorporated (VPHM) numbers were lowered at Jefferies. Shares are now seen reaching $33. Estimates were also lowered on FDA approval of generic Vancocin, Jefferies said. Buy rating.

ViroPharma Incorporated numbers were lowered at Oppenheimer. Shares are now seen reaching $27. Estimates were also lowered on denial of Citizen's Petition related to Vancocin, Oppenheimer said. Outperform rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:






Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs